- Telehealth Visits
- Insurance plan information
Charles Dollbaum, MD, PhD
Medical Oncology • Internal Medicine- Telehealth Visits
- Insurance plan information
Charles Dollbaum, MD, PhD
Medical Oncology • Internal Medicine- Telehealth Visits
- Insurance plan information
On this page
Education & training
Board certification
- Medical Oncology, American Board of Internal Med/Medical Oncology
- Internal Medicine, American Board of Internal Medicine
Fellowship
- Hematology - Oncology, UCSF Medical Center - OMAG
Internship
- Cedars-Sinai Medical Center (prior privileges)
Degree
- MD, University of California Los Angeles
My expertise
Locations
Clinical Trials query: q=health_gateway_id_ss%3A%28%22408%22%29+AND+status_s%3A%28%22Recruiting%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Clinical+Trial%22
Puiblications query: q=health_gateway_id_ss%3A%28%22408%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Publication%22
Showing 1-6 of 9 reviews
- July 1, 20255 out of 5 Stars
Dr. Dollbaum is always 100% present and I am so grateful to have him as my doctor
- May 1, 20255 out of 5 Stars
I very much appreciate that I never felt rushed and that Dr. Dollbaum was available for questions and to discuss concerns.
- April 9, 20253 out of 5 Stars
Fair
- March 11, 20255 out of 5 Stars
Dr. Dollbaum is very good at making you feel at ease and he answers all questions!
- November 18, 20245 out of 5 Stars
Dr.Dollbaum is the sweetest man. He really cares for his patients. A heart of gold. I can talk freely with him and know he is listening.
- October 30, 20245 out of 5 Stars
Dr Dollbaum was caring, responded clearly to my questions and concerns, seem to genuinely care. He was thorough and did not rush me, which I appreciate.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.